The Efficacy and Safety between Intradetrusor OnabotulinumtoxinA Injection and Combined Pharmacotherapy in Patients with Refractory Overactive Bladder: A Randomized Controlled Trial.

Meng-Hsuen Hsieh,Jiun-Chyi Hwang,Tsung-Hsien Su,Hui-Hsuan Lau
{"title":"The Efficacy and Safety between Intradetrusor OnabotulinumtoxinA Injection and Combined Pharmacotherapy in Patients with Refractory Overactive Bladder: A Randomized Controlled Trial.","authors":"Meng-Hsuen Hsieh,Jiun-Chyi Hwang,Tsung-Hsien Su,Hui-Hsuan Lau","doi":"10.1097/ju.0000000000004660","DOIUrl":null,"url":null,"abstract":"PURPOSE\r\nTo investigate whether intradetrusor onabotulinumtoxinA injection demonstrates superior efficacy and fewer side effects compared to combined pharmacotherapy in patients with refractory overactive bladder.\r\n\r\nMATERIAL AND METHODS\r\nIn this single-center, open-label, randomized trial, patients with urodynamically confirmed detrusor overactivity and persistent symptoms despite at least two months of single pharmacotherapy were randomized to receive onabotulinumtoxinA injection (100 U) or combined pharmacotherapy with solifenacin 5 mg and mirabegron 25 mg. Assessments at baseline and 12 weeks included voiding parameters, adverse events, and patient-reported outcomes using the Urogenital Distress Inventory, the Incontinence Impact Questionnaire, and the Overactive Bladder Symptom Score.\r\n\r\nRESULTS\r\nOf 74 patients enrolled, 66 completed the study (33 per group). Both treatments reduced urgency episodes to a median of 2.0 per 24 hours at 12 weeks. The mean difference between groups was -0.1 (95% CI: -1.5 to 1.4; p = 0.925), indicating no significant difference. Improvements in urinary frequency, nocturia, urge incontinence, and quality-of-life measures were observed in both groups, without significant differences. However, adverse effects such as dry mouth, constipation, and blurred vision were significantly more common with pharmacotherapy (all p < 0.05).\r\n\r\nCONCLUSION\r\nBoth intradetrusor onabotulinumtoxinA and combined pharmacotherapy improved symptoms in women with refractory overactive bladder. OnabotulinumtoxinA demonstrated a more favorable safety profile and represents an appropriate option for patients sensitive to systemic anticholinergic effects or preferring non-daily interventions.","PeriodicalId":501636,"journal":{"name":"The Journal of Urology","volume":"11 1","pages":"101097JU0000000000004660"},"PeriodicalIF":0.0000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of Urology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/ju.0000000000004660","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

PURPOSE To investigate whether intradetrusor onabotulinumtoxinA injection demonstrates superior efficacy and fewer side effects compared to combined pharmacotherapy in patients with refractory overactive bladder. MATERIAL AND METHODS In this single-center, open-label, randomized trial, patients with urodynamically confirmed detrusor overactivity and persistent symptoms despite at least two months of single pharmacotherapy were randomized to receive onabotulinumtoxinA injection (100 U) or combined pharmacotherapy with solifenacin 5 mg and mirabegron 25 mg. Assessments at baseline and 12 weeks included voiding parameters, adverse events, and patient-reported outcomes using the Urogenital Distress Inventory, the Incontinence Impact Questionnaire, and the Overactive Bladder Symptom Score. RESULTS Of 74 patients enrolled, 66 completed the study (33 per group). Both treatments reduced urgency episodes to a median of 2.0 per 24 hours at 12 weeks. The mean difference between groups was -0.1 (95% CI: -1.5 to 1.4; p = 0.925), indicating no significant difference. Improvements in urinary frequency, nocturia, urge incontinence, and quality-of-life measures were observed in both groups, without significant differences. However, adverse effects such as dry mouth, constipation, and blurred vision were significantly more common with pharmacotherapy (all p < 0.05). CONCLUSION Both intradetrusor onabotulinumtoxinA and combined pharmacotherapy improved symptoms in women with refractory overactive bladder. OnabotulinumtoxinA demonstrated a more favorable safety profile and represents an appropriate option for patients sensitive to systemic anticholinergic effects or preferring non-daily interventions.
肌内注射单肉毒杆菌毒素与联合药物治疗难治性膀胱过动症的疗效和安全性:一项随机对照试验。
目的探讨肌内注射单肉毒杆菌毒素a治疗难治性膀胱过动症是否优于联合药物治疗,且副作用更小。材料与方法在这项单中心、开放标签、随机试验中,尿动力学证实的逼尿肌过度活动且单药治疗至少2个月后症状仍持续的患者被随机分为两组,分别接受单肉毒杆菌毒素注射(100u)或联合索利那新5mg和mirabegron 25mg的药物治疗。基线和12周的评估包括排尿参数、不良事件和患者报告的结果,使用泌尿生殖窘迫量表、尿失禁影响问卷和膀胱过度活动症状评分。结果74例入组患者中,66例完成了研究(每组33例)。在12周时,两种治疗方法均将紧急发作减少到中位数每24小时2.0次。组间平均差异为-0.1 (95% CI: -1.5 ~ 1.4;P = 0.925),差异无统计学意义。两组患者在尿频、夜尿、急迫性尿失禁和生活质量方面均有改善,无显著差异。然而,不良反应如口干、便秘、视力模糊在药物治疗中更为常见(均p < 0.05)。结论肌内注射肉毒杆菌毒素和联合药物治疗可改善难治性膀胱过动症患者的症状。OnabotulinumtoxinA显示出更有利的安全性,对于对全身抗胆碱能作用敏感或更喜欢非日常干预的患者来说,它是一种合适的选择。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信